Señales en vivo de URGN | Maximiza tus Ganancias con Getagraph.com

VENDER 108539 min ago

@ $19.19

Emitido: 13 feb 2024 @ 11:02

Retorno: -26.27%

Señal anterior: feb 12 - 15:11

Señal anterior: Comprar

Retorno: -0.20 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
Volumen de hoy	135 619
Volumen promedio	364 868
Capitalización de mercado	482.83M
EPS	$0 ( 2024-03-21 )
Próxima fecha de ganancias	( $-0.930 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.99
ATR14	$0.0290 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Schoenberg Mark	Sell	12 000	Ordinary Shares
2024-01-31	Kim Dong	Buy	3 333	Ordinary Shares
2022-03-25	Kim Dong	Buy	20 000	Stock Option (right to buy)
2024-02-01	Smith Jason Drew	Sell	3 328	Ordinary Shares
2024-02-01	Smith Jason Drew	Sell	1 248	Ordinary Shares

INSIDER POWER
58.85
Last 96 transactions
Buy: 1 308 776 \| Sell: 407 960

Volumen Correlación

Largo: 0.26 (neutral)

Corto: -0.02 (neutral)

Signal:(62.511) Neutral

Urogen Pharma Ltd Correlación

10 Correlaciones Más Positivas
SVAC	0.916
GOODM	0.907
TLGT	0.891
MTSL	0.871
NSTS	0.866
TTWO	0.86
LUNG	0.851
PAIC	0.851
RMNI	0.845
RCM	0.833

10 Correlaciones Más Negativas
LWAC	-0.955
SRAC	-0.919
AMRB	-0.902
LMRKN	-0.889
NETE	-0.881
KNSA	-0.847
UTHR	-0.847
RAVN	-0.84
OFS	-0.831
TECH	-0.828

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Urogen Pharma Ltd Correlación - Moneda/Commodity

0.18
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.17
( neutral )

0.09
( neutral )

Urogen Pharma Ltd Finanzas

Annual	2023
Ingresos:	$82.71M
Beneficio Bruto:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2023
Ingresos:	$82.71M
Beneficio Bruto:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2022
Ingresos:	$64.36M
Beneficio Bruto:	$56.70M (88.11 %)
EPS:	$-4.79

FY	2021
Ingresos:	$48.04M
Beneficio Bruto:	$42.89M (89.27 %)
EPS:	$-4.96

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.